Pigmentary Changes Are the Defining Trial Finding
Trial-reported pigmentary changes include:
- Diffuse skin darkening — expected pharmacologic effect, present in >90% of treated participants.
- Darkening of existing nevi — documented across trial arms.
- Appearance of new pigmented lesions — documented; annual dermatologic surveillance is part of the EU EPP treatment program.
The melanoma question has been addressed across multiple post-marketing surveillance reports for SCENESSE (the approved product). The published surveillance data has not identified an increased melanoma rate in the small EPP-treated population. Dermatologic monitoring remains mandatory in the EU treatment program.
For users using research-peptide melanotan-1 cosmetically, that dermatologic surveillance is typically absent — which community sources flag as the most significant gap between research-peptide use and the trial-validated use pattern.
Note on labeling: the events below come from r/peptides, r/melanotan, and community sources for research-peptide melanotan-1 used for cosmetic tanning. They overlap with trial findings but reflect a different exposure pattern (lower per-dose, daily, longer duration).
Nausea after early injections
Community sources commonly describe nausea in the first 1-7 days of subcutaneous dosing, often most severe within 2 hours of injection. Self-reported community sources commonly describe starting at very low doses (10-25% of the typical maintenance dose) and slowly titrating upward to reduce this.
Facial flushing within 30 minutes
Self-reported community timelines describe brief warmth and visible flush during the first 30-60 minutes after injection, fading without intervention.
Increased appetite
Community reports cluster around modestly increased appetite, attributed by community sources to the MC4 receptor activation that also drives the melanocortin family's hunger effects. The pattern is less pronounced than melanotan-2 in community reports.
Mole and pigmentation changes
The community-reported pigmentary pattern aligns with trial findings: diffuse skin darkening is the targeted effect; community sources commonly describe new freckles and darkening of existing moles. Community sources also commonly describe annual full-body dermatologic exams as the appropriate monitoring response — though many users don't do them.
Fatigue and headache
The most consistent community feedback for the first week is brief headache and mild fatigue, fading within 7-10 days.
Less Common but Notable Events
- Sexual side effects — less common than with melanotan-2 (which acts at MC4 more strongly). Sparse community reports of altered libido at higher doses.
- Yawning/stretching reflex — documented mechanism finding for melanocortin agonists; sparse in community reports.
- Allergic-type reactions — rare in trials and community sources.
Dose-Response Patterns
Trial dosing — 16 mg implant every 60 days — produces a pharmacologic plateau, not the pulsatile exposure of daily injections. Community-reported research-peptide dosing typically uses 0.5-1 mg subcutaneous daily during loading (1-2 weeks), then 0.5-1 mg 2-3x weekly for maintenance. Self-reported community sources describe:
- Nausea more pronounced during loading.
- Pigmentary effects scaling with cumulative dose, not per-injection dose.
- Mole changes appearing in users with multiple loading cycles.
Dose-Pause and Discontinuation Patterns
Trial protocols paused dosing for protocol-defined adverse events. Community sources commonly describe stopping immediately and consulting a dermatologist when new pigmented lesions appear that look atypical. Pause-and-resume for nausea or GI events is uncommon in community reports for melanotan-1 (less common than for melanotan-2).
The most-cited community trigger for permanent discontinuation: dermatologist flagging a mole as needing biopsy or removal.
